Research Topics
Genomes and Genes | Stewart A FactorSummaryAffiliation: Emory University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Primary progressive freezing gait: a syndrome with many causesStewart A Factor
Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA
Neurology 66:411-4. 2006..PPFG is not a distinct disorder but a syndrome with diverse causes. Long-term follow-up (> or =10 years) and postmortem are required for accurate diagnosis. PNLD may be the primary form of disease...- Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystoniaStewart A Factor
Parkinson s Disease and Movement Disorders Center of Albany Medical Center, Albany, New York, USA
Mov Disord 20:1152-60. 2005..BoNT B therapy provides long-term benefit for CD patients but the magnitude of response diminishes over time. The cause of this decay is probably multifactorial. AR and NAR CD patients respond in a similar fashion... 
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysisStewart A Factor
Emory University School of Medicine, Department of Neurology, 1841 Clifton Road NE, Atlanta, GA 30329, USA
J Neurol Neurosurg Psychiatry 82:564-8. 2011..To test the hypothesis that postural instability with falling (PIF) and freezing of gait (FOG) are distinct subtypes of the postural instability/gait disturbance (PIGD) form of Parkinson's disease (PD)...- Disease-related and genetic correlates of psychotic symptoms in Parkinson's diseaseStewart A Factor
Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
Mov Disord 26:2190-5. 2011..We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders... - The clinical spectrum of freezing of gait in atypical parkinsonismStewart A Factor
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
Mov Disord 23:S431-8. 2008..Both syndromes are heterogeneous but PSP seems to be the most common cause. CBD and DLB can also present as PPFG. FOG is a common feature of AP and although typically occurring late in disease may also be an early symptom... - Current and future treatments in multiple system atrophyChristine D Esper
Stewart A Factor, DO Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road NE, Room 327, Atlanta, GA 30329, USA
Curr Treat Options Neurol 9:210-23. 2007..The management for this disorder currently includes symptomatic and palliative strategies, as well as family education and support; the ultimate goal is to improve the quality of life for patients and their caregivers... - Current status of symptomatic medical therapy in Parkinson's diseaseStewart A Factor
Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, Georgia 30329, USA
Neurotherapeutics 5:164-80. 2008..The article closes with a discussion of future directions and new drugs under development... - Genetic association between alpha-synuclein and idiopathic Parkinson's diseaseDenise M Kay
New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD... 
Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's diseaseHaydeh Payami
Genomics Institute, New York State Department of Health, Wadsworth Center, PO Box 22002, Albany, NY 12201 2002, USA
Genet Epidemiol 34:92-9. 2010..MAP is intended as a descriptive method, to complement standard statistical techniques. Although originally developed for age patterns, MAP is equally useful for visualizing any quantitative trait...- Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's diseaseTaye H Hamza
New York State Department of Health Wadsworth Center, Albany, New York, USA
Nat Genet 42:781-5. 2010..The genetic association with HLA supports the involvement of the immune system in Parkinson's disease and offers new targets for drug development... - Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug classDonald L Bliwise
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
Mov Disord 27:1118-24. 2012..The apparent divergent dose-dependent effects of drug class in Parkinson's disease are anticipated by basic science studies of the sleep/wake cycle under different pharmacological agents... - Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's diseaseDenise M Kay
Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
Genet Test 10:221-7. 2006..Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential... - Evidence for more than one Parkinson's disease-associated variant within the HLA regionErin M Hill-Burns
New York State Department of Health Wadsworth Center, Albany, New York, United States of America
PLoS ONE 6:e27109. 2011..60). Our findings suggest more than one PD-HLA association; either different alleles of the same gene, or separate loci... - Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patientsDenise M Kay
Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
Ann Neurol 61:47-54. 2007..We present a comprehensive sequence analysis of parkin in control subjects... - Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristicsAnn B Sollinger
Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
Parkinsonism Relat Disord 16:177-80. 2010..Future studies should focus on additional risk factors for MCI subtypes and their possible progression to frank dementia... - Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinicsDenise M Kay
Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
Mov Disord 21:519-23. 2006..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date... - Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year intervalRichard F Seegal
Wadsworth Center, New York State Department of Health, Albany, NY 12201 0509, USA
J Expo Sci Environ Epidemiol 21:234-46. 2011..The results may aid in further understanding the toxicological/epidemiological consequences of exposure to PCBs in humans... - Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffeeTaye H Hamza
New York State Department of Health Wadsworth Center, Albany, New York, USA
PLoS Genet 7:e1002237. 2011..GRIN2A may be a useful pharmacogenetic marker for subdividing individuals in clinical trials to determine which medications might work best for which patients... - Threatening auditory hallucinations and Cotard syndrome in Parkinson diseaseStewart A Factor
Parkinson s Disease and Movement Disorders Center of Albany Medical Center, New York 12205, USA
Clin Neuropharmacol 27:205-7. 2004.... - Daytime REM sleep in Parkinson's diseaseDonald L Bliwise
Department of Neurology, Emory University School of Medicine, Atlanta, GA 30329, USA
Parkinsonism Relat Disord 19:101-3. 2013..In this study we examined REM sleep during daytime Maintenance of Wakefulness Testing (MWT) in PD patients... - Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopaYoland Smith
Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA
Neuropsychopharmacology 37:213-46. 2012.... - Excessive daytime sleepiness in cervical dystoniaLynn Marie Trotti
Emory University School of Medicine, Department of Neurology, Atlanta, GA 30329, USA
Parkinsonism Relat Disord 15:784-6. 2009..This preliminary finding of excessive daytime sleepiness in a substantial portion of CD patients suggests that further investigation into disordered sleep in CD is warranted... - Progressive supranuclear palsyChristine D Esper
Department of Neurology Emory University School of Medicine, Atlanta, GA, USA
Rev Neurol Dis 4:209-16. 2007..Although there are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits, several supportive measures are available... - Diabetes mellitus among parkinsonian patients treated chronically with clozapineHubert H Fernandez
Department of Neurology, University of Florida, Gainesville, FL, USA
Parkinsonism Relat Disord 10:439-41. 2004..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this... - Failure of recognition of drug-induced parkinsonism in the elderlyChristine D Esper
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
Mov Disord 23:401-4. 2008..Cessation of the offending agent results in improvement of symptoms and would eliminate the need for dopaminergic agents, which are known to commonly cause side effects in the elderly... - Movement disorders emergencies. Part 1: Hypokinetic disordersBradley J Robottom
Department of Neurology, University of Maryland School of Medicine, 110 S Paca Street, Baltimore, MD 21201, USA
Arch Neurol 68:567-72. 2011..Emergency complications related to the management of Parkinson disease, including falling, motor fluctuations, and psychiatric issues, will also be reviewed... - Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family historyAmi R Rosen
Department of Neurology, Emory University, 1841 Clifton Rd, Atlanta, GA 30329, USA
Neurogenetics 8:263-70. 2007..These findings suggest the existence of common genetic and/or environmental factors that predispose to both AD and PD in the subset of cases with positive family history of both neurodegenerative diseases... - Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging studyRichard F Seegal
Wadsworth Center, New York State Department of Health, Albany, NY 12201 0509, USA
Neurobiol Dis 38:219-25. 2010.... - Movement disorders emergencies Part 2: hyperkinetic disordersBradley J Robottom
Department of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3 S 128, Baltimore, MD 21201, USA
Arch Neurol 68:719-24. 2011..Part 2 provides a diagnostic approach to the recognition and treatment of hyperkinetic movement disorders emergencies by identifying phenomenology and reviewing common etiologies... - Tardive dyskinesiaPratibha G Aia
Department of Neurology, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA, 30329, USA
Curr Treat Options Neurol 13:231-41. 2011..This has the potential to worsen TD in the long run... - Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapyChristine D Esper
Emory University School of Medicine, Department of Neurology, Movement Disorders Program, Atlanta, GA 30329, USA
Parkinsonism Relat Disord 16:438-41. 2010..We conclude that LPD is rare, most commonly the result of tardive and primary dystonia. Botulinum toxin therapy may be very effective but needs to be utilized with care because of the possibility for the development of dysphagia... - The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementiaSujana Reddy
Department of Psychiatry, Albany Medical Center, Albany, New York 12205, USA
Mov Disord 17:676-81. 2002..We conclude that quetiapine is effective in improving psychosis in approximately 80% of PD patients both with and without dementia. Patients with dementia seem to have a higher propensity for worsening of motor symptoms... - The natural history of the syndrome of primary progressive freezing gaitStewart A Factor
Parkinson s Disease and Movement Disorder Center of Albany Medical Center, 215 Washington Ave Extension, Albany, NY 12203, USA
Arch Neurol 59:1778-83. 2002..However, confusion remains about its clinical presentation, natural history, and classification... - Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's diseaseStewart A Factor
Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York 12205, USA
Neurology 62:S12-7. 2004..Subutaneous intermittent bolus injects are also useful in patients post operatively who are unable to take oral medications... - Non-human primate FOG develops with advanced parkinsonism induced by MPTP TreatmentGonzalo J Revuelta
Department of Neurology, Division of Movement Disorders, Emory University School of Medicine, Atlanta, GA, USA
Exp Neurol 237:464-9. 2012..03). The unique features of FOG in PD can be replicated in severely parkinsonian macaques, and this represents the first description of a FOG animal model... - Dystonia in AIDS: report of four casesStewart A Factor
Albany Medical Center, Department of Neurology, Albany, New York 12205, USA
Mov Disord 18:1492-8. 2003..When dystonia is seen in AIDS patients, its pattern may be a clue to the ultimate cause... - Pharmacology of atypical antipsychoticsStewart A Factor
Parkinson's Disease and Movement Disorder Center of Albany Medical Center, Albany, New York, USA
Clin Neuropharmacol 25:153-7. 2002 - Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystoniaCharles H Adler
Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
Mov Disord 17:158-61. 2002..We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period... - Lack of evidence for an association between UCHL1 S18Y and Parkinson's diseaseCarolyn M Hutter
Department of Epidemiology, University of Washington, Seattle, WA, USA
Eur J Neurol 15:134-9. 2008..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease... - LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia agoCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Am J Hum Genet 79:752-8. 2006..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas... - Advanced therapies for movement disorders in neurotherapeuticsMahlon R Delong
Neurotherapeutics 5:163. 2008 - Risperidone and Parkinson's diseaseStewart A Factor
Mov Disord 17:221-2. 2002 - Exploring gene-environment interactions in Parkinson's diseaseColin C McCulloch
Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
Hum Genet 123:257-65. 2008..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk... - Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease riskKaren M Powers
Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
Mov Disord 23:88-95. 2008..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated... - Cervical dystonia in twinsStewart A Factor
Mov Disord 17:846-7. 2002 - Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's diseaseCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Ann Neurol 62:137-44. 2007..We sought to replicate these findings... - Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulationStewart A Factor
Mov Disord 22:148-9. 2007 - Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyAlexis Elbaz
INSERM, Unit 708, Paris, France
Lancet Neurol 5:917-23. 2006..INTERPRETATION: Our results do not lend support to the finding that the 13 SNPs reported in the original genome-wide association study are genetic susceptibility factors for Parkinson's disease... - Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's diseaseJoseph H Friedman
Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 21:2078-81. 2006..While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising... - Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three casesMarjorie A Murphy
Department of Ophthalmology, Rhode Island Hospital, Brown Medical School MAM, RI 02903, USA
J Clin Neurosci 12:941-5. 2005..We describe three cases diagnosed during life as PSP but found to have another neurologic disorder at autopsy. No explanation for the gaze palsies was found in any case...